Axsome Therapeutics (NASDAQ:AXSM) CFO Sells $2,255,040.00 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie sold 12,000 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total transaction of $2,255,040.00. Following the sale, the chief financial officer directly owned 42,588 shares of the company’s stock, valued at approximately $8,003,136.96. This represents a 21.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Axsome Therapeutics Stock Performance

AXSM traded down $1.02 during trading on Friday, hitting $185.96. The stock had a trading volume of 426,610 shares, compared to its average volume of 855,001. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. Axsome Therapeutics, Inc. has a 12 month low of $86.99 and a 12 month high of $191.50. The company has a 50 day simple moving average of $159.39 and a 200-day simple moving average of $133.10.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The firm had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The business’s revenue for the quarter was up 63.2% compared to the same quarter last year. On average, sell-side analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analysts Set New Price Targets

AXSM has been the subject of a number of research analyst reports. Oppenheimer reiterated an “outperform” rating and set a $220.00 price target on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Wells Fargo & Company upped their target price on shares of Axsome Therapeutics from $157.00 to $193.00 and gave the company an “overweight” rating in a research note on Tuesday, January 13th. Needham & Company LLC reissued a “buy” rating and issued a $225.00 price target on shares of Axsome Therapeutics in a report on Monday, January 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 14th. Finally, Royal Bank Of Canada boosted their price objective on shares of Axsome Therapeutics from $212.00 to $219.00 and gave the stock an “outperform” rating in a report on Wednesday. Nineteen analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $203.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AXSM. Versant Capital Management Inc grew its stake in shares of Axsome Therapeutics by 20,300.0% during the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after purchasing an additional 203 shares during the last quarter. First Horizon Corp bought a new position in Axsome Therapeutics in the 3rd quarter worth approximately $34,000. Optiver Holding B.V. lifted its holdings in Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after buying an additional 130 shares in the last quarter. Essex Investment Management Co. LLC bought a new position in Axsome Therapeutics in the 3rd quarter valued at $38,000. Finally, Advisory Services Network LLC acquired a new stake in shares of Axsome Therapeutics in the 3rd quarter valued at $40,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.